Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study
- PMID: 21810685
- PMCID: PMC3624700
- DOI: 10.1200/JCO.2011.34.7625
Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study
Abstract
Purpose: Older adults are vulnerable to chemotherapy toxicity; however, there are limited data to identify those at risk. The goals of this study are to identify risk factors for chemotherapy toxicity in older adults and develop a risk stratification schema for chemotherapy toxicity.
Patients and methods: Patients age ≥ 65 years with cancer from seven institutions completed a prechemotherapy assessment that captured sociodemographics, tumor/treatment variables, laboratory test results, and geriatric assessment variables (function, comorbidity, cognition, psychological state, social activity/support, and nutritional status). Patients were followed through the chemotherapy course to capture grade 3 (severe), grade 4 (life-threatening or disabling), and grade 5 (death) as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events.
Results: In total, 500 patients with a mean age of 73 years (range, 65 to 91 years) with stage I to IV lung (29%), GI (27%), gynecologic (17%), breast (11%), genitourinary (10%), or other (6%) cancer joined this prospective study. Grade 3 to 5 toxicity occurred in 53% of the patients (39% grade 3, 12% grade 4, 2% grade 5). A predictive model for grade 3 to 5 toxicity was developed that consisted of geriatric assessment variables, laboratory test values, and patient, tumor, and treatment characteristics. A scoring system in which the median risk score was 7 (range, 0 to 19) and risk stratification schema (risk score: percent incidence of grade 3 to 5 toxicity) identified older adults at low (0 to 5 points; 30%), intermediate (6 to 9 points; 52%), or high risk (10 to 19 points; 83%) of chemotherapy toxicity (P < .001).
Conclusion: A risk stratification schema can establish the risk of chemotherapy toxicity in older adults. Geriatric assessment variables independently predicted the risk of toxicity.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Similar articles
-
Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol.BMC Cancer. 2019 Nov 27;19(1):1153. doi: 10.1186/s12885-019-6377-7. BMC Cancer. 2019. PMID: 31775667 Free PMC article.
-
Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement.J Geriatr Oncol. 2019 Mar;10(2):202-209. doi: 10.1016/j.jgo.2018.08.010. Epub 2018 Sep 14. J Geriatr Oncol. 2019. PMID: 30224184
-
Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in Japan.J Geriatr Oncol. 2022 Nov;13(8):1216-1222. doi: 10.1016/j.jgo.2022.07.011. Epub 2022 Aug 23. J Geriatr Oncol. 2022. PMID: 36008273
-
Geriatric Assessment and Tools for Predicting Treatment Toxicity in Older Adults With Cancer.Cancer J. 2017 Jul/Aug;23(4):206-210. doi: 10.1097/PPO.0000000000000269. Cancer J. 2017. PMID: 28731942 Review.
-
Elderly patients with advanced NSCLC: The value of geriatric evaluation and the feasibility of CGA alternatives in predicting chemotherapy toxicity.Pulmonology. 2019 Jan-Feb;25(1):40-50. doi: 10.1016/j.pulmoe.2018.07.004. Epub 2018 Sep 25. Pulmonology. 2019. PMID: 30266308 Review.
Cited by
-
The Edmonton Frail Scale as a screening score for frailty in oncogeriatrics.Front Med (Lausanne). 2024 Sep 30;11:1466366. doi: 10.3389/fmed.2024.1466366. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39403280 Free PMC article.
-
A case report: deep and durable response to low-dose lenvatinib and tislelizumab in an elderly patient with advanced intrahepatic cholangiocarcinoma.Front Pharmacol. 2024 Sep 26;15:1447582. doi: 10.3389/fphar.2024.1447582. eCollection 2024. Front Pharmacol. 2024. PMID: 39391699 Free PMC article.
-
The Use of Artificial Intelligence in Predicting Chemotherapy-Induced Toxicities in Metastatic Colorectal Cancer: A Data-Driven Approach for Personalized Oncology.Diagnostics (Basel). 2024 Sep 19;14(18):2074. doi: 10.3390/diagnostics14182074. Diagnostics (Basel). 2024. PMID: 39335752 Free PMC article.
-
Frailty and pre-frailty associated with long-term diminished physical performance and quality of life in breast cancer and hematopoietic cell transplant survivors.Aging (Albany NY). 2024 Sep 26;16(18):12432-12442. doi: 10.18632/aging.206109. Epub 2024 Sep 26. Aging (Albany NY). 2024. PMID: 39330993 Free PMC article.
-
Discontinuation of immune checkpoint inhibitors in hepatocellular carcinoma: a retrospective cohort study.J Gastrointest Oncol. 2024 Aug 31;15(4):1698-1711. doi: 10.21037/jgo-24-216. Epub 2024 Aug 28. J Gastrointest Oncol. 2024. PMID: 39279966 Free PMC article.
References
-
- Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–2765. - PubMed
-
- Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–2067. - PubMed
-
- Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: A 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–4631. - PubMed
-
- Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293:1073–1081. - PubMed
-
- Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091–1097. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
